BACKGROUND: The Drug Burden Index (DBI), a measure of exposure to anticholinergic and sedative medications, has been independently associated with physical and cognitive function in a cross-sectional analysis of community-dwelling older persons participating in the Health, Aging and Body Composition study. Here we evaluate the association between DBI and functional outcomes in Health, Aging and Body Composition study participants over 5 years. METHODS: DBI was calculated at years 1 (baseline), 3, and 5, and a measure of the area under the curve for DBI (AUCDB) over the whole study period was devised and calculated. Physical performance was measured using the short physical performance battery, usual gait speed, and grip strength. The association of DBI at each time point and AUCDB with year 6 function was analyzed in data from participants with longitudinal functional measures, controlling for sociodemographics, comorbidities, and baseline function. RESULTS: Higher DBI at years 1, 3, and 5 was consistently associated with poorer function at year 6. On multivariate analysis, a 1-unit increase in AUCDB predicted decreases in short physical performance battery score of .08 (P=.01), gait speed of .01 m/s (P=.004), and grip strength of .27 kg (P=.004) at year 6. CONCLUSION: Increasing exposure to medication with anticholinergic and sedative effects, measured with DBI, is associated with lower objective physical function over 5 years in community-dwelling older people.
BACKGROUND: The Drug Burden Index (DBI), a measure of exposure to anticholinergic and sedative medications, has been independently associated with physical and cognitive function in a cross-sectional analysis of community-dwelling older persons participating in the Health, Aging and Body Composition study. Here we evaluate the association between DBI and functional outcomes in Health, Aging and Body Composition study participants over 5 years. METHODS:DBI was calculated at years 1 (baseline), 3, and 5, and a measure of the area under the curve for DBI (AUCDB) over the whole study period was devised and calculated. Physical performance was measured using the short physical performance battery, usual gait speed, and grip strength. The association of DBI at each time point and AUCDB with year 6 function was analyzed in data from participants with longitudinal functional measures, controlling for sociodemographics, comorbidities, and baseline function. RESULTS: Higher DBI at years 1, 3, and 5 was consistently associated with poorer function at year 6. On multivariate analysis, a 1-unit increase in AUCDB predicted decreases in short physical performance battery score of .08 (P=.01), gait speed of .01 m/s (P=.004), and grip strength of .27 kg (P=.004) at year 6. CONCLUSION: Increasing exposure to medication with anticholinergic and sedative effects, measured with DBI, is associated with lower objective physical function over 5 years in community-dwelling older people.
Authors: J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace Journal: J Gerontol A Biol Sci Med Sci Date: 2000-04 Impact factor: 6.053
Authors: F Landi; A Russo; R Liperoti; M Cesari; C Barillaro; M Pahor; R Bernabei; G Onder Journal: Clin Pharmacol Ther Date: 2006-12-27 Impact factor: 6.875
Authors: Anne B Newman; Varant Kupelian; Marjolein Visser; Eleanor M Simonsick; Bret H Goodpaster; Stephen B Kritchevsky; Frances A Tylavsky; Susan M Rubin; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2006-01 Impact factor: 6.053
Authors: Y-J Cao; D E Mager; E M Simonsick; S N Hilmer; S M Ling; B G Windham; V Crentsil; S Yasar; L P Fried; D R Abernethy Journal: Clin Pharmacol Ther Date: 2007-08-22 Impact factor: 6.875
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Arch Intern Med Date: 2007-04-23
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph T Hanlon; Brenda W J H Penninx; David K Blough; Suzanne G Leveille; Margaret B Artz; Jack M Guralnik; Dave M Buchner Journal: J Am Geriatr Soc Date: 2006-02 Impact factor: 5.562
Authors: Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon Journal: Ann Intern Med Date: 2007-06-05 Impact factor: 25.391
Authors: Nicholas M Wilson; Sarah N Hilmer; Lyn M March; Jian Sheng Chen; Danijela Gnjidic; Rebecca S Mason; Ian D Cameron; Philip N Sambrook Journal: Drugs Aging Date: 2012-02-01 Impact factor: 3.923
Authors: Eija Lönnroos; Danijela Gnjidic; Sarah N Hilmer; J Simon Bell; Hannu Kautiainen; Raimo Sulkava; Sirpa Hartikainen Journal: Drugs Aging Date: 2012-05-01 Impact factor: 3.923
Authors: Alexander Bennett; Danijela Gnjidic; Mark Gillett; Peter Carroll; Slade Matthews; Kristina Johnell; Johan Fastbom; Sarah Hilmer Journal: Drugs Aging Date: 2014-03 Impact factor: 3.923
Authors: Jennifer G Naples; Zachary A Marcum; Subashan Perera; Shelly L Gray; Anne B Newman; Eleanor M Simonsick; Kristine Yaffe; Ronald I Shorr; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2015-10 Impact factor: 5.562
Authors: Jordan D Haag; Amanda Z Davis; Robert W Hoel; Jeffrey J Armon; Laura J Odell; Ross A Dierkhising; Paul Y Takahashi Journal: Am Health Drug Benefits Date: 2016-07